[go: up one dir, main page]

BRPI0915142A2 - polipeptídeos, ácido nucleico e usos dos mesmos - Google Patents

polipeptídeos, ácido nucleico e usos dos mesmos

Info

Publication number
BRPI0915142A2
BRPI0915142A2 BRPI0915142A BRPI0915142A BRPI0915142A2 BR PI0915142 A2 BRPI0915142 A2 BR PI0915142A2 BR PI0915142 A BRPI0915142 A BR PI0915142A BR PI0915142 A BRPI0915142 A BR PI0915142A BR PI0915142 A2 BRPI0915142 A2 BR PI0915142A2
Authority
BR
Brazil
Prior art keywords
polypeptides
nucleic acid
nucleic
acid
Prior art date
Application number
BRPI0915142A
Other languages
English (en)
Inventor
Frederic Madec
Keith Foster
Philip Marks
Phill Lecane
Original Assignee
Syntaxin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0810782.3A external-priority patent/GB0810782D0/en
Priority claimed from GB0820965A external-priority patent/GB0820965D0/en
Application filed by Syntaxin Ltd filed Critical Syntaxin Ltd
Publication of BRPI0915142A2 publication Critical patent/BRPI0915142A2/pt
Publication of BRPI0915142A8 publication Critical patent/BRPI0915142A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
BRPI0915142A 2008-06-12 2009-06-11 Polipeptídeos, ácido nucleico e usos dos mesmos BRPI0915142A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0810782.3A GB0810782D0 (en) 2008-06-12 2008-06-12 Suppression of cancers
GB0820965A GB0820965D0 (en) 2008-11-17 2008-11-17 Suppression of cancers
PCT/GB2009/050666 WO2009150470A2 (en) 2008-06-12 2009-06-11 Suppression of cancers

Publications (2)

Publication Number Publication Date
BRPI0915142A2 true BRPI0915142A2 (pt) 2016-02-16
BRPI0915142A8 BRPI0915142A8 (pt) 2018-01-02

Family

ID=41417178

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915142A BRPI0915142A8 (pt) 2008-06-12 2009-06-11 Polipeptídeos, ácido nucleico e usos dos mesmos

Country Status (13)

Country Link
US (2) US10240138B2 (pt)
EP (2) EP2310029B1 (pt)
JP (1) JP5799397B2 (pt)
KR (1) KR101731655B1 (pt)
CN (2) CN102083451A (pt)
AU (1) AU2009259034B2 (pt)
BR (1) BRPI0915142A8 (pt)
CA (1) CA2726092A1 (pt)
ES (1) ES2732205T3 (pt)
HK (1) HK1246809A1 (pt)
IL (1) IL209854A (pt)
WO (1) WO2009150470A2 (pt)
ZA (1) ZA201008425B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
GB0803068D0 (en) 2008-02-20 2008-03-26 Health Prot Agency Cross-linked biological indicator
US10466245B2 (en) 2008-02-20 2019-11-05 The Secretary Of State For Health Covalently linked thermostable kinase for decontamination process validation
ES2750651T3 (es) * 2008-06-12 2020-03-26 Ipsen Bioinnovation Ltd Proteínas de fusión para uso en el tratamiento de acromegalia
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
GB0820970D0 (en) * 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
AU2015268754B2 (en) * 2008-11-17 2018-01-18 Ipsen Bioinnovation Limited Suppression of cancer
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
DK2603600T3 (da) 2010-08-13 2019-03-04 Aileron Therapeutics Inc Peptidomimetiske makrocyklusser
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
CA2852468A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
SG10201606775YA (en) 2012-02-15 2016-10-28 Aileron Therapeutics Inc Peptidomimetic macrocycles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CA2887285A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
CN105518143B (zh) * 2013-03-15 2020-02-21 北京凯得尔森生物技术有限公司 融合蛋白分子和它的使用方法
US9216210B2 (en) * 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
RU2748576C2 (ru) 2016-04-19 2021-05-27 Гриффон Фармасьютикалз Интернешнл Са. Пэгилированные биологически активные пептиды и их применение
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
TWI822723B (zh) 2018-01-29 2023-11-21 英商艾普森生物製藥有限公司 非神經元性 SNARE 裂解的肉毒桿菌神經毒素、裂解 hSNAP-23 之活體外方法、及經修飾 BoNT/A L 鏈蛋白酶之用途
GB201815817D0 (en) * 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
CN114933657B (zh) * 2021-08-25 2024-02-02 上海交通大学医学院 神经生长因子突变体重组蛋白及其应用

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US317941A (en) 1885-05-12 Half to theodoee f
US282328A (en) 1883-07-31 eager
US257998A (en) 1882-05-16 Harrow
US173311A (en) 1876-02-08 Improvement in stone-gleaners
US204171A (en) 1878-05-28 Improvement in rings for preventing hogs from rooting
US440039A (en) 1890-11-04 Cough remedy
US502438A (en) 1893-08-01 Apparatus for producing cold and ice
US207759A (en) 1878-09-03 Improvement in accordions
US520225A (en) 1894-05-22 Skirt-protecting garment
US376555A (en) 1888-01-17 Banana-carrier
US100571A (en) 1870-03-08 Improved stove-shelf and drier
US248771A (en) 1881-10-25 Lap-ring
US8057A (en) 1851-04-22 Cofkee-roasteb
US397169A (en) 1889-02-05 campbell
US422A (en) 1837-10-06 Galley ob cooking-stove for ships of wab
US394727A (en) 1888-12-18 scully
US261885A (en) 1882-08-01 Ornamental glass and process of etching the same
US4291022A (en) 1975-03-11 1981-09-22 Sandoz Ltd. Organic compounds
US4133782A (en) 1976-06-07 1979-01-09 The Salk Institute For Biological Studies Somatostatin analogs with dissociated biological activities
US4190575A (en) 1977-12-27 1980-02-26 American Home Products Corporation Polypeptides related to somatostatin
IT1105131B (it) 1977-06-08 1985-10-28 Merck & Co Inc Peptidi analoghi della somatostatina dotati di piu' lunga e maggiore attivita' biologica e relativo procedimento di protezione
US4211693A (en) 1977-09-20 1980-07-08 The Salk Institute For Biological Studies Peptides with para-substituted phenylalanine
LU78191A1 (de) 1977-09-28 1979-05-25 Ciba Geigy Ag Verfahren zur herstellung von neuen cyclopeptiden
US4190648A (en) 1979-03-13 1980-02-26 Merck & Co., Inc. Peptides having somatostatin activity
US4316890A (en) 1979-03-16 1982-02-23 Ciba-Geigy Corporation Peptides and processes for the manufacture thereof
US4328214A (en) 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
US4310518A (en) 1979-10-31 1982-01-12 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4235886A (en) 1979-10-31 1980-11-25 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4369179A (en) 1979-12-14 1983-01-18 Ciba-Geigy Corporation Acylpeptides
US4282143A (en) 1980-06-13 1981-08-04 American Home Products Corporation Octapeptides lowering growth hormone
US4360516A (en) 1981-04-13 1982-11-23 Merck & Co., Inc. Modified D-retro cyclic hexapeptide somatostatin analogs
ATE14226T1 (de) 1981-12-24 1985-07-15 Ciba Geigy Ag Cyclische octapeptide und pharmazeutische praeparate davon, sowie verfahren zur herstellung derselben und ihre anwendung.
FR2522655B1 (fr) 1982-03-05 1987-03-06 Sanofi Sa Analogues de la somatostatine possedant une liaison du type hydrazide et medicaments en contenant
US4522813A (en) 1983-10-27 1985-06-11 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4659693A (en) 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4725577A (en) 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US4650787A (en) 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
US4585755A (en) 1985-04-29 1986-04-29 Merck & Co., Inc. Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents
US4904642A (en) 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4803261A (en) 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
HU906340D0 (en) 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols
US4871717A (en) 1987-01-07 1989-10-03 Administrators Of The Tulane Educational Fund Peptides
WO1989002897A1 (en) 1987-09-24 1989-04-06 The Administrators Of The Tulane Educational Fund Therapeutic peptides
US5084555A (en) 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
JPH03502328A (ja) 1988-02-01 1991-05-30 ジ・アップジョン・カンパニー 極性末端基類を有するレニン抑制ペプチド類
ZA895838B (en) 1988-08-18 1991-03-27 Syntex Inc Pharmaceutical compounds
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990003980A1 (en) 1988-10-14 1990-04-19 Administrators Of The Tulane Educational Fund Therapeutic peptides
CA2012115C (en) 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
KR0173119B1 (ko) 1989-04-26 1999-02-01 닐 에이. 밴스로우 선형 소마토스타틴 유사체
DE69027767T2 (de) 1989-12-08 1997-01-02 Univ Tulane Oktapeptidanaloge von somatostatin mit threonin in position 6
AU651976B2 (en) 1990-05-04 1994-08-11 The Administrators Of The Tulane Eductional Fund Novel synthetic GRF analogs
CA2081890A1 (en) 1990-05-09 1991-11-10 David H. Coy Cyclized and linear therapeutic peptides
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
HU207104B (en) 1991-01-25 1993-03-01 Biosignal Kutato Fejlesztoe Kf Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
WO1992018531A1 (en) 1991-04-09 1992-10-29 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
US6083915A (en) 1991-05-10 2000-07-04 Biomeasure, Inc. Method for treating liver cancer
WO1993015766A1 (en) 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens
US5240561A (en) 1992-02-10 1993-08-31 Industrial Progress, Inc. Acid-to-alkaline papermaking process
AU5668894A (en) 1992-11-13 1994-06-08 The Administrators Of The Tulane Eductional Fund Ghrh agonists
AU5727194A (en) 1992-11-13 1994-06-08 The Administrators Of The Tulane Eductional Fund Ghrh agonists
DE69432758T2 (de) 1993-08-09 2004-02-19 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Therapeutisch wirksame peptidderivate
US5550212A (en) 1993-12-17 1996-08-27 The Administrators Of The Tulane Educational Fund Analogues of hGH-RH(1-29)NH2 having antagonistic activity
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
ATE170873T1 (de) 1995-03-13 1998-09-15 Biomeasure Inc Bombesin-analogen
CA2218173A1 (en) 1995-04-14 1996-10-17 The Administrators Of The Tulane Educational Fund Analogs of growth hormone-releasing factor
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
US5942489A (en) 1996-05-03 1999-08-24 The Administrators Of The Tulane Educational Fund HGH-RH(1-29)NH2 analogues having antagonistic activity
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
WO1998008528A1 (en) 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
SE507528C2 (sv) 1996-10-16 1998-06-15 Teknoskand Invent Ab Låsanordning
US5968903A (en) 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
DK1084146T3 (da) 1998-05-13 2003-02-03 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf
US6380265B1 (en) 1998-07-09 2002-04-30 W. R. Grace & Co.-Conn. Dispersion of fine porous inorganic oxide particles and processes for preparing same
DK1346731T3 (da) 1998-07-22 2007-04-10 Osprey Pharmaceuticals Ltd Konjugater til behandling af inflammatoriske forstyrrelser og tilsvarende vævsskade
EP1100532A2 (en) 1998-07-30 2001-05-23 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Methods of using lanreotide, a somatostatin analogue
US8790897B2 (en) * 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6057422A (en) 1998-11-25 2000-05-02 The Administrators Of The Tulane Educational Fund Antagonistic analogs of GH-RH inhibiting IGF-I and -II
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
RU2263680C2 (ru) 1999-06-04 2005-11-10 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас Агонисты рецепторов нейромедина в и соматостатина
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7369973B2 (en) * 2000-06-29 2008-05-06 Object Reservoir, Inc. Method and system for representing reservoir systems
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
JP2004520345A (ja) 2001-01-12 2004-07-08 ワラター・ファーマシューティカルズ・インク 糖尿病を有する被験者にガストリン／ｃｃｋ受容体リガンド及びｅｇｆ受容体リガンド組成物を用いた島細胞新生治療方法の効果持続
EP1599213A4 (en) 2003-02-24 2009-07-15 Ira Sanders CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
TW200517400A (en) 2003-08-05 2005-06-01 Univ Tulane Antagonistic analogs of GH-RH (2003)
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
CA2578911A1 (en) 2004-09-01 2006-03-09 Allergan, Inc. Degradable clostridial toxins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
WO2006059093A2 (en) * 2004-12-01 2006-06-08 Health Protection Agency Fusion proteins
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8052979B2 (en) * 2005-03-15 2011-11-08 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
JP5134540B2 (ja) 2005-09-19 2013-01-30 アラーガン、インコーポレイテッド クロストリジウム毒素活性化クロストリジウム毒素
WO2007106115A1 (en) 2006-03-14 2007-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US7993656B2 (en) * 2006-07-11 2011-08-09 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
JP2009543558A (ja) 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
GB0815264D0 (en) 2008-08-21 2008-09-24 Syntaxin Ltd Non-cytotoxic proteins
KR20120062772A (ko) * 2009-08-14 2012-06-14 알러간, 인코포레이티드 글루카곤 유사 호르몬 재표적화된 엔도펩티다아제를 사용하여 암을 치료하는 방법
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins

Also Published As

Publication number Publication date
CN102083451A (zh) 2011-06-01
US10550377B2 (en) 2020-02-04
HK1246809A1 (zh) 2018-09-14
EP2310029A2 (en) 2011-04-20
US20140219983A1 (en) 2014-08-07
BRPI0915142A8 (pt) 2018-01-02
US10240138B2 (en) 2019-03-26
ES2732205T3 (es) 2019-11-21
EP2310029B1 (en) 2019-04-03
ZA201008425B (en) 2012-04-25
AU2009259034B2 (en) 2013-10-31
EP3473643A1 (en) 2019-04-24
WO2009150470A2 (en) 2009-12-17
JP5799397B2 (ja) 2015-10-28
US20110165137A1 (en) 2011-07-07
IL209854A (en) 2013-09-30
KR101731655B1 (ko) 2017-05-11
JP2011523859A (ja) 2011-08-25
CN107446053A (zh) 2017-12-08
WO2009150470A3 (en) 2010-07-15
IL209854A0 (en) 2011-02-28
AU2009259034A1 (en) 2009-12-17
CA2726092A1 (en) 2009-12-17
KR20110028492A (ko) 2011-03-18

Similar Documents

Publication Publication Date Title
BRPI0915142A2 (pt) polipeptídeos, ácido nucleico e usos dos mesmos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI0922790A2 (pt) peptídeos de ligação sparc e usos dos mesmos
BRPI0914682A2 (pt) compostos de heteroarila e usos dos mesmos
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI1013943A2 (pt) Composto cetais e usos dos mesmos.
BRPI0910702A2 (pt) polipeptídeos de fator ix modificados e usos dos mesmos
DK2129797T3 (da) Nukleinsyrepåvisning
DK2282764T3 (da) Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf
BR112012006501A2 (pt) polipeptídios e usos dos mesmos
BRPI1011970A2 (pt) compostos pirazolil-acrilonitrila e usos dos mesmos.
BRPI0822337A2 (pt) Folatos, composições e usos dos mesmos
BRPI0908906A2 (pt) compostos heterocíclicos e usos dos mesmos
SMT201600335B (it) Proteine leganti eterodimeri e loro usi
BRPI1014997A2 (pt) compostos heteroarila e usos dos mesmos
BRPI1012340A (pt) proteínas de ligação específica e usos das mesmas
BRPI0918122A2 (pt) molécula de diaboy, diaboy, e mólecula dart
DK2049671T3 (da) Regulatoriske nukleinsyreelementer
BRPI0909469A2 (pt) compostos de oximetileno de arila e usos dos mesmos
BRPI0814582A2 (pt) Dispositivo, método, e, usos de um método, e da quantidade de ácidos nucleicos virais totais.
BRPI0912225A2 (pt) peptídeos de direcionamento lisossomais e usos dos mesmos
BRPI0911060A2 (pt) polipeptídeos de fator vii que são modificados e usos dos mesmos
BRPI0821310A2 (pt) Conjugados polipeptídeos-ácido nucleico e usos dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: IPSEN BIOINNOVATION LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: IPSEN BIOINNOVATION LIMITED (GB)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]